Table 1.
Demographic and clinical data
| Demographic and clinical variables | SCD stable (n = 253) | SCD progression (n = 49) | P value |
|---|---|---|---|
| Male/female (%male) | 136/117 (54%) | 27/22 (55%) | .64 |
| Age (y) | 61 (9) | 69 (6) | <.01 |
| Education (range 1–7)∗ | 5 (1) | 5 (1) | .32 |
| Scanner system (1 T/3T) | 151/102 | 31/18 | .84 |
| Clinical | |||
| Cardiovascular risk factors | |||
| Smoking, current (n (%) yes) | 30 (12%) | 5 (9%) | .81 |
| Diabetes (n (%) yes) | 23 (9%) | 3 (6%) | .41 |
| Hypertension (n (%) yes) | 52 (20%) | 15 (30%) | .13 |
| Blood pressure (systolic/diastolic mm Hg) | 139/84 | 147/84 | .37/.87 |
| Family history cardiovascular disease (n (%) yes) | 81 (32%) | 15 (31%) | .38 |
| Family history dementia (n (%) yes) | 100 (39%) | 22 (45%) | .06 |
| MMSE | 28 (2) | 28.0 (2) | .10 |
| APOE ε4 positive† | 80 (37%) | 22 (53%) | .05 |
| Follow-up time | 3 (2) | 4 (3) | .12 |
| Diagnosis at progression | NA | aMCI n = 25 (51%) | |
| mMCI n = 5 (10%) | |||
| naMCI n = 2 (4%) | |||
| Probable AD n = 9 (18%) | |||
| bvFTD n = 3 (6%) | |||
| VaD n = 4 (8%) | |||
| PPA n = 1 (2%) | |||
| CSF β-amyloid1-42‡ | 857 (237) | 705 (303) | <.01 |
| CSF total tau‡ | 268 (146) | 448 (258) | <.001 |
| Preclinical AD§ | |||
| Stage 0 (%) | n = 114 (64%) | n = 8 (29%) | <.001 |
| Stage I (%) | n = 20 (12%) | n = 4 (14%) | .44 |
| Stage II (%) | n = 12 (7%) | n = 10 (36%) | <.01 |
| SNAP (%) | n = 31 (18%) | n = 6 (21%) | .34 |
Abbreviations: AD, Alzheimer's disease; aMCI, amnestic MCI; APOE, apolipoprotein E; bvFTD, behavioral FTD; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; mMCI, multidomain MCI; MMSE, mini-mental state examination; NA, not applicable; naMCI, nonamnestic MCI; PPA, primary progressive aphasia, SCD, subjective cognitive decline; SD, standard deviation; SNAP, suspected non-Alzheimer's pathophysiology; VaD, vascular dementia.
NOTE. Data are presented as n (%) or mean (SD). Comparisons between groups were made with analyses of variance for continuous variables and χ2 tests for discrete variables. An AD biomarker profile was defined based on the following cutoffs Aβ42: 640 and tau: 375 ng/L.
According to the Verhage classification.
Fourteen percent missing data.
Thirty-two percent missing data.
According to the National Institute on Aging-Alzheimer's Association preclinical AD stages (2012).